Reuters logo
U.S. FDA approves Biogen's hemophilia B drug Alprolix
March 28, 2014 / 8:57 PM / 4 years ago

U.S. FDA approves Biogen's hemophilia B drug Alprolix

March 28 (Reuters) - Biogen Idec Inc has won U.S. approval for its long-acting hemophilia B treatment Alprolix, the U.S. Food and Drug Administration said on Friday.

Hemophilia B is a rare, inherited disorder in which a person’s blood does not clot properly, potentially leading to prolonged bleeding and bruising. It affects about 4,000 people in the United States and 25,000 worldwide.

Alprolix is a bioengineered version of the blood coagulation factor IX, a protein needed for normal blood clotting. Biogen is developing the drug in partnership with Swedish Orphan Biovitrum AB. It received approval in Canada a week ago. (Reporting by Toni Clarke in Washington; Editing by David Gregorio)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below